Arranged in conjunction with key healthcare professionals in the immunotherapy field.
Our symposia are designed to help keep healthcare professionals informed about the latest advancements in ECP. If you missed our symposia in 2024, take a look at the recordings on-demand below.
Upcoming Symposia
Past Symposia
Sep 18, 2025
DGTI 2025 Clinical Symposium: Save the Date
Mannheim, Germany
Sep 12, 2025
ADO 2025 Clinical Symposium: Extracorporeal photopheresis current status
Essen, Germany
Jul 1, 2025
ESOT 2025 Clinical Symposium: Save the Date
London, United Kingdom
Filter by:
May 5, 2025
GITMO 2025 Clinical Symposium: cGVHD: Evidence and new experiences with ECP
16th International Congress on Lung Transplantation Clinical Symposium: ECP in Lung Transplantation: From treating to preventing – What? How? What for?
Austrotransplant 2023 Clinical Symposium: ECP after solid organ transplantation, possible role in patients with ABMR, infections and high risk patients
DGTI 2023 Clinical Symposium: Extracorporeal photopheresis: Collection efficiency of ECP systems - Vascular accesses in the ICU This event is in German
This website is intended for residents in Europe and the Middle East. For residents outside of Europe and the Middle East, please refer to the relevant sites below.
Following CVC’s acquisition of Therakos, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the transition services agreement (TSA), which is the reason for your redirection.
The Therakos Institute is intended for Health Care Professionals only and not intended for the general public.
IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE
Indications
The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:
Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)
The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:
Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)
Contraindications
THERAKOSTM Photopheresis is contraindicated in:
Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3
Patients who have coagulation disorders or who have previously had a splenectomy
Warnings and Precautions
THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.
Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.
Adverse Events
Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.
IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS
Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.
Warnings and Precautions
Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.
Filter by:
France
US
Canada
Australia